228 related articles for article (PubMed ID: 22438913)
1. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.
Kim JG; Kang MJ; Yoon YK; Kim HP; Park J; Song SH; Han SW; Park JW; Kang GH; Kang KW; Oh DY; Im SA; Bang YJ; Yi EC; Kim TY
PLoS One; 2012; 7(3):e33322. PubMed ID: 22438913
[TBL] [Abstract][Full Text] [Related]
2. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
[TBL] [Abstract][Full Text] [Related]
3. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).
Pavlicek A; Lira ME; Lee NV; Ching KA; Ye J; Cao J; Garza SJ; Hook KE; Ozeck M; Shi ST; Yuan J; Zheng X; Rejto PA; Kan JL; Christensen JG
Mol Cancer Ther; 2013 Dec; 12(12):2929-39. PubMed ID: 24107449
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
Ii M; Li H; Adachi Y; Yamamoto H; Ohashi H; Taniguchi H; Arimura Y; Carbone DP; Imai K; Shinomura Y
Clin Cancer Res; 2011 Aug; 17(15):5048-59. PubMed ID: 21642381
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
7. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
[TBL] [Abstract][Full Text] [Related]
8. [Abnormal expression of insulin-like growth factor-I receptor and inhibitory effect of its transcription intervention on nude mice xenograft tumor].
Yao M; Yan XD; Cai Y; Gu JJ; Yang XL; Pan LH; Wang L; Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):846-851. PubMed ID: 27978931
[No Abstract] [Full Text] [Related]
9. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.
Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D
Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941
[TBL] [Abstract][Full Text] [Related]
10. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.
Shang Y; Mao Y; Batson J; Scales SJ; Phillips G; Lackner MR; Totpal K; Williams S; Yang J; Tang Z; Modrusan Z; Tan C; Liang WC; Tsai SP; Vanderbilt A; Kozuka K; Hoeflich K; Tien J; Ross S; Li C; Lee SH; Song A; Wu Y; Stephan JP; Ashkenazi A; Zha J
Mol Cancer Ther; 2008 Sep; 7(9):2599-608. PubMed ID: 18790743
[TBL] [Abstract][Full Text] [Related]
11. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K
Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637
[TBL] [Abstract][Full Text] [Related]
12. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
[TBL] [Abstract][Full Text] [Related]
13. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
14. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
15. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
19. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
20. Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells.
Sarfstein R; Nagaraj K; LeRoith D; Werner H
Cells; 2019 Nov; 8(12):. PubMed ID: 31771180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]